GlassScriptPhysician profile
Saba Medhane
NPI 1205893542
$2,183.50
in general payments reported to CMS, 2019-2025
30 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $231 · 2023: $328 · 2024: $673 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $336.98 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $184.41 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novo Nordisk INC | $162.93 | 2019-2025 | Wegovy, Saxenda |
| Daiichi Sankyo INC. | $141.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $133.77 | 2019-2025 | Breztri, Airsupra |
| Shield Therapeutics INC | $121.22 | 2024 | |
| Abbvie INC. | $118.25 | 2019-2024 | |
| Glaxosmithkline, LLC. | $116.49 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $104.48 | 2019-2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $100.26 | 2019-2020 | |
| Exact Sciences Corporation | $85.25 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $70.57 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.44 | 2019-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $54.71 | 2024-2025 | Givlaari |
| Lilly USA, LLC | $51.39 | 2020-2023 | Mounjaro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.10 | 2023-2024 | |
| Astellas Pharma US INC | $28.57 | 2023 | Veozah |
| Tactile Systems Technology INC | $26.65 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.64 | 2024 | Keveyis |
| Bausch Health US, LLC | $24.39 | 2024 | Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.03 | 2025 | Xifaxan |
| Akebia Therapeutics INC | $23.71 | 2024 | Auryxia |
| Teva Pharmaceuticals USA, INC. | $23.01 | 2019-2020 | |
| Inspire Medical Systems, INC. | $22.99 | 2025 | Inspire |
| Phadia US INC. | $18.36 | 2024 | Immunocap |
| Allergan, INC. | $18.09 | 2020 | |
| Corcept Therapeutics | $15.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.92 | 2019 | |
| Sanofi Pasteur INC. | $14.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Medhane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.